Rodney Young Net Worth

The estimated Net Worth of Rodney Kb Young is at least $2.32 Million dollars as of 10 May 2022. Mr. Young owns over 5,000 units of RAPT Therapeutics stock worth over $19,462 and over the last 5 years he sold RAPT stock worth over $0. In addition, he makes $2,296,220 as Chief Financial Officer at RAPT Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Young RAPT stock SEC Form 4 insiders trading

Rodney has made over 1 trades of the RAPT Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of RAPT stock worth $52,650 on 10 May 2022.

The largest trade he's ever made was buying 5,000 units of RAPT Therapeutics stock on 10 May 2022 worth over $52,650. On average, Rodney trades about 833 units every 0 days since 2019. As of 10 May 2022 he still owns at least 10,084 units of RAPT Therapeutics stock.

You can see the complete history of Mr. Young stock trades at the bottom of the page.

Rodney Young biography

Rodney K. B. Young serves as Chief Financial Officer of the Company. Prior to that, he served as Chief Financial Officer at Cellerant Therapeutics, Inc., a biotechnology company, from June 2015 to November 2019. From May 2014 to February 2015, Mr. Young served as Chief Financial Officer at Aimmune Therapeutics, Inc., a public biotechnology company, and from September 2005 to December 2013 he served as Chief Financial Officer and Vice President, Finance and Administration at StemCells, Inc., a public biotechnology company. Mr. Young obtained an M.B.A. in Finance and Accounting from the Booth School of Business at the University of Chicago and received his B.A. in Economics from the University of Chicago.

What is the salary of Rodney Young?

As the Chief Financial Officer of RAPT Therapeutics, the total compensation of Rodney Young at RAPT Therapeutics is $2,296,220. There are no executives at RAPT Therapeutics getting paid more.

How old is Rodney Young?

Rodney Young is 57, he's been the Chief Financial Officer of RAPT Therapeutics since 2019. There are 7 older and 7 younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.

What's Rodney Young's mailing address?

Rodney's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at RAPT Therapeutics

Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.

What does RAPT Therapeutics do?

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Complete history of Mr. Young stock trades at RAPT Therapeutics

RAPT Therapeutics executives and stock owners

RAPT Therapeutics executives and other stock owners filed with the SEC include:

• Rodney Young,
  Chief Financial Officer
• Brian Wong,
  President, Chief Executive Officer, Director
• Dirk Brockstedt,
  Chief Scientific Officer
• Dr. Brian Russell Wong M.D., Ph.D.,
  CEO, Pres & Director
• Dr. William Ho,
  Chief Medical Officer
• Dr. Dirk G. Brockstedt Ph.D.,
  Chief Scientific Officer
• Mary Gray,
  Independent Director
• Wendye Robbins,
  Independent Director
• William Rieflin,
  Independent Director
• Linda Kozick,
  Independent Director
• Michael Giordano,
  Independent Director
• Peter Svennilson,
  Director
• William Ho,
  Chief Medical Officer
• Lisa Moore,
  Vice President - Business Development and Strategy
• Phyllis Gray,
  Vice President of Human Resources
• Paul Kassner,
  Senior Vice President - Quantitative and Computational Biology
• Dr. David Wustrow,
  Sr. VP of Drug Discovery & Preclinical Devel.
• Dr. Paul Kassner,
  Sr. VP of Quantitative & Computational Biology
• Steve Young Ph.D.,
  VP of Technology
• Rodney K. B. Young,
  CFO, Principal Accounting Officer & Sec.
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Perkins Caufield & Byers Xv...,
  
• David V Goeddel,
  Director
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Group Ii, Lp Column Group I...,
  
• Fund L.P.Topspin Biotech Fu...,
  
• Karen C Lam,
  VP, Finance and Controller
• Lori Lyons Williams,